1239852-33-5

Usage

Uses

Used in Pharmaceutical Industry:
Benzyl (6-Azaspiro[2.5]octan-1-yl)carbamate is used as a pharmaceutical intermediate for the synthesis of various drugs, particularly those used for the treatment of diseases affecting the central nervous system. Its unique structure and functional group make it a valuable component in the development of medications with potential anticonvulsant, anxiolytic, and muscle relaxant properties.
Used in Research and Development:
In the field of medicinal chemistry and neuroscience, benzyl (6-Azaspiro[2.5]octan-1-yl)carbamate is used as a research compound to study its potential therapeutic effects and explore its mechanism of action. This helps scientists and researchers to better understand its pharmacological properties and develop new drugs with improved efficacy and safety profiles.
Used in Drug Formulation:
Benzyl (6-Azaspiro[2.5]octan-1-yl)carbamate may be used in the formulation of drugs to enhance their therapeutic effects, improve bioavailability, and reduce side effects. Its unique structure and functional group can potentially be utilized to modify the pharmacokinetics and pharmacodynamics of the final drug product, leading to better patient outcomes.

Upstream product

• 1239852-32-4 tert-butyl 1-(benzyloxycarbonylamino)-6-azaspiro[2.5]octane-6-carboxylate 
• 871727-05-8 (±)-6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid 
• 100-51-6 benzyl alcohol 

Relevant academic research and scientific papers

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.

DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The invention relates to a compound of the general formula (I) in which R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy, NR8R9 group; m, n, o and p are independently an integer equal to 0, 1, 2 or 3; A is a covalent bond or a C1-8-alkylene group; R1 is an optionally substituted aryl or heteroaryl group; R3 is a hydrogen or fluorine atom or a C1-6-alkyl group or a trifluoromethyl group; R4 is an optionally substituted 5-member heterocyclic compound; the compound being in the form of a base or acid addition salt. The invention also relates to the therapeutic use thereof.